Furthermore, we found evidence of heterogeneity between genetically predicted cALT and cancers of colorectal, prostate, kidney, skin, non‐Hodgin Lymphoma, breast, cervical, endometrial, and liver & bile duct, and between imaging‐and‐biopsy confirmed NAFLD and cancers of esophagus, prostate, breast, and endometrial (Tables S6 and S7). Here, CETN2 is linked to cancer.